ERBB2 and gastric cancer: Based on this hypothesis, a phase II trial of induction pembrolizumab and trastuzumab followed by 5FU/platinum/trastuzumab and pembrolizumab was conducted in patients with untreated metastatic HER2 positive GC (82).